Background: Delay to diagnosis following an abnormal screening result is associated with morbidity such as anxiety, but its effect on prognosis is unknown. Methods: Using data from the Somme area breast cancer screening programme (France), we identified 29,511 women aged 50-69 years who underwent screening between 1996 and 2000. We prospectively followed women with an abnormal screening result until completion of the assessment process and evaluated the effect of delay to notification, diagnosis and treatment on prognostic indicators. Results: Women with high-suspicion screens (n=976) compared with those with intermediate-suspicion screens (n= 1008) were investigated mare promptly, presented larger tumours (62% vs 42%, p=0.03), and were more likely to be lymph node positive (36% vs 17%, p=0.02). Compared with a delay to dioqnosis s l month, the odds ratio for tumour size greater than 10 mm was 1.4 (95% confidence interval[CI], 0.90-1.90) For a delay of 1 to:o::;6 months, and 1.8 (95% CI, 1.02-2.85) For a delay >6 months. Similarly, a 1.4-fold and 2-fold increased risk of lymph node involvement was observed for delays of >3 to :0::;6 months and >6 months, respectively, compared with the reFerence interval. Conclusion: The authors' findings suggest that women with high-suspicion mammograms were investigated mare promptly, and that delays to diagnosis of asymptomatic breast carcinoma >6 months were associated with progression of the cancer measured by tumour size > 10 mm and lymph node metastasis.
INTRODUCTION
S in ce the late 1980s, organised breast cancer screening programmes have been developed in many countries in order to reduce breast cancer mortality. 1-4 Some women with abnormal screening results are subsequently found to have breast cancer on further assessment. For women without cancer, subsequent investigations may cause morbidity, including anxiety.r" Since screening is proposed to women in good health, and as breast cancer is absent in most women with abnormal screening results, the morbidity associated with an abnormal result should be reduced by providing timely follow-up. Despite the existence of practice guidelines recommending that work-up should be conducted promptly, previous publications had shown a variable delay to diagnosis following abnormal breast screening. 9 -13 These studies have reponed discordant results, as some of them have suggested that delays of 60 days or longer after onset of symptoms to definitive diagnosis have no effect or may even improve the prognosis. Recently, Olivotto et al. indicated that a delay of more than 20 weeks in the diagnosis of asymptomatic breast cancer from an initial suspicious screen was associated with increased tumour size and an increased risk of lymph node metastasis." However, it is unknown whether cumulative delays before treatment of three to four months after a screen-detected abnormality can affect the risk of cancer progression or the woman's chance of cure." Some authors have suggested that physicians expedite investigations depending on the level of suspicion of cancer. [9] [10] [11] In France, a breast cancer screening programme was introduced at the end of 1989 and is now available in about one third of all French administrative areas [AQ1]. The women and their family physicians are usually notified about the screening result, and the family physician organises subsequent referrals when the result is abnor-maI. 14--1 5 We used the results of the Somme area breast cancer screening programme which was initiated in December 1990.
The aim of this study was to assess the influence of the screening results on the delay to notification of these results, the delay to diagnosis and the delay treatment of breast carcinoma, and to measure, in particular, the effect of the delay to diagnosis on prognostic factors in these asymptomatic women.
METHODS

Data source
The Somme area breast cancer screening programme was initiated in December 1990 and was designed to screen a target population of about 50,000 women between the ages of 50 and 69 years. Women were invited to attend a screening session every 36 months. The protocol during the first round (1 December 1990 to December 1993) consisted of an oblique view of both breasts performed in one of the private or public X-ray clinics in the area. Two different radiologists examined the screens. When the radiologists disagreed on their findings, a third reading was performed by a panel of three different radiologists.
Study population
We decided to analyse data just from the 1996-2000 period for three reasons: firstly, the inevitable delay in notification www.jmedscreen.com and verification of cases in the Somme area cancer registry; secondly, the introduction of a second view (oblique and cranio-caudal) for the mammograms of both breasts for the second round; and thirdly, the participation of a panel of radiologists for review of mammograms in 1995.
We defined breast cancer suspicion as 'high' or 'intermediate'. A case with abnormal results on the first analysis by two different radiologists was considered to be a 'high suspicion' screen, and an abnormality detected by the panel of radiologists following discordant results of the first two mammogram readings was considered to be an 'intermediate suspicion' screen.
Determination of prognostic indicators and delays to notification, diagnosis and treatment
Breast cancers were defined as epithelial invasive cancers or ductal carcinoma in situ (DCIS) of the breast. In the case of a simultaneously diagnosed second breast cancer, only the tumour with the poorer prognosis was considered. Tumour staging was performed according to the International Union Against Cancer(UICC) classification.
The prognostic outcomes evaluated were tumour size and axillary lymph node metastasis. Tumour size was determined on the pathological specimen (98%) or clinically (2%) and was classified as greater than, or less than or equal to 10 mm. Lymph node status was determined pathologically and the results were classified as either positive (one or more involved lymph nodes), or negative (no lymph node involvement).
We evaluated the number of days required to complete three assessment intervals. Delay to notification of the mammogram result was defined as the interval between the abnormal screen and notification of the result to the woman and her family physician. Delay to diagnosis was defined as the interval between the abnormal screen and the pathological diagnosis of breast carcinoma. Delay to treatment was defined as the interval between the abnormal screen and initiation of treatment (surgery etc.). The duration of the three assessment intervals was determined for all women with validated dates for the start points and end points of interest, who completed the assessment procedures studied. Possible confounding factors for the delays of notification, diagnosis and treatment were age at screen (SO-59, 60-70 years), screen year and screening history (first, second, and third programme screen).
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Statistical analysis
The effects of the level of suspicion, the screen year, the age at screen and the screen history were examined for the three assessment intervals by comparing the delays by a Student t-test [AQ2]and analysis of variance (ANOVA). Chi-square tests were used to evaluate differences between women with high -suspicion screens and intermediate-suspicion screens. Logistic regression was performed to estimate the odds ratios and 95% confidence limits for the effect of delay on prognostic indicators (tumour size and positive lymph node status), using cases diagnosed between zero and one month after screening as the reference category, adjusted for possible confounding factors (screen year, age at screen, screen history).
RESULTS
Out of a total of 29,511 screened women, 1984 had an 'intermediate' or 'high' suspicion screen (6.7%). Median age at screen was 59 years. A total of 157 cancers was detected (5.2 cancers per 1000 women screened and 6.2% of those with abnormal screening results). For the three cases with bilateral disease, the cancer with the higher stage was analysed. Approximately 78% of these cancers had highsuspicion screens. Overall, 42% of women presented tumours less than or equal to 10 mrn. and 31 % had one or more lymph node metastases. No information was obtained for three cases (0.7%).
High-suspicion cases were investigated more promptly. The mean interval from abnormal screen to notification of the woman and her family physician was 9.8 and 11.8 days for women with high and intermediate suspicion screens, respectively (p<O.OOI). Women with high-suspicion screens were investigated more promptly than women with intermediate suspicion screens. The mean interval from screening mammogram to diagnosis and treatment for women with high-suspicion mammograms was 58.6 and 71.2 days, respectively. These delays were significantly different from those observed for women with intermediate-suspicion mammograms ( tumours greater than 10 mm (62% vs 42%, Chi-square test: p=0.03) and were more likely to have positive axillary lymph nodes (36% vs 17%; Chi-square test: p=0.02) ( Table 2) . Variables other than level of suspicion were not associated with delays and did not influence the observed relationship between delays to notification, diagnosis and treatment (Table 1) . However, the delay to notification of the results to the family physician was longer in 1999 and 2000. The proportion of cases with tumour size > 10 mm and lymph node involvement increased with increasing delay to diagnosis (Table 3) . A delay of between >1 month and <:;6 months was associated with a lA-fold higher risk of tumour size greater than 10 mm (delay of >1 month to <:;3 months had an odds ratio: 1.37; 95% CI: 0.91-1.63. A delay of >3 months to <:;6 months had an odds ratio: 1.32; 95% CI: 0.86-1.96). A delay of >6 months was associated with a 1.8fold higher risk of tumour size greater than 10 mm (odds ratio: 1.77; 95% CI: 1.02-2.85). Similarly, a delay of between >3 months and <:;6 months was associated with a 1.4-fold higher risk of lymph node involvement (odds ratio: 1.41; 95% CI: 0.98-1.98) and a delay >6 months was associated with a two fold higher risk of lymph node involvement (odds ratio: 2.01; 95% CI: 1.29-3.03) compared with the reference interval.
DISCUSSION
The capacity of screening programmes to reduce breast cancer mortality partly depends on adequate follow-up of women with abnormal screening results. 2,9.12-I>.16-17 We have demonstrated the influence of screening results in a breast cancer mass screening programme. Our results revealed that physicians tended to accelerate the diagnostic process for women with more suspicious abnormalities and women with high-suspicion screens were more promptly notified and investigated. This improvement in early diagnosis of breast cancer appears to be particularly important, as women with high-suspicion screens presented larger tumours and were more likely to be lymph node positive.v'""
A pattern of increased likelihood of lymph node metastasis and increased tumour size was observed for a delay greater than one month between an abnormal breast screen and Ganry, Peng, Dubreuil diagnosis of breast carcinoma. Compared with the reference interval «1 month). a delay of between >3 months and <:;6 months was associated with a 104 fold increase in the risk of lymph node metastases, and a delay >6 months was associated with a 2.0 fold increase. A longer delay to diagnosis was also associated with increasing tumour size.
Analysis of the interval from diagnosis to treatment did not reveal any significant differences. Our results tended to show that delay to treatment was not correlated with the screening results, but with the results of further investigations.
In the past, the motivation for prompt and complete investigations was to reduce anxiety and inadequate follow-Up.11 However, reducing delays may also improve the prognosis of these women and may improve the efficacy of breast screening programmes and reduce specific mortality.l'v'" These results are consistent with a recent systematic review of published studies showing that delays of 3-6 months between symptom onset and treatment are associated with lower survival rates."
Despite this informal prioritisation process, the delay to diagnosis was still 12 weeks or longer for 11 % of women. As mentioned previously, in the Somme area breast screening programme, once the family physician is notified of abnormalities, they initiate and coordinate the assessment process.":" The advantage of this system is that the family physician remains an important participant in the diagnostic sequence. However, such multiple visits to various health care providers increases the time to diagnosis.
The diagnostic delay in breast cancer mass screening for asymptomatic women can be due to various complex components related to patient characteristics the general practitioner's level of awareness and attention, compliance with the screening programme, the skills of the medical professionals (i.e. radiologists) or the waiting time for admission to a cancer institute (private or public establishments). 12 Patient-, physician-and system-related delays cannot be distinguished."!' Waiting times can be affected by the women themselves and their anxiety concerning the result of the screen, by physicians or by the integration of the organised screening programme within the Somme area health care system. Olivotto et al. used the term 'suspicion bias' to describe the expedited diagnostic procedures observed in the case of a preliminary highly suspicious result. A short delay to diagnosis therefore appears to improve the prognosis, as the suspicion bias artificially increases the proportion of poor prognosis cancers diagnosed promptly after an abnormal screen, affecting the findings of studies concerning the prognostic implications of diagnostic delays." The definition of high-suspicion varies between the different programmes and this suspicion bias can only be partially controlled. We showed that the various procedures (delay to notification and delay to diagnosis) were expedited more promptly for women with high-suspicion screens, but these shorter delays did not significantly increase the proportion of poor prognostic indicators in this category of women.
In summary, for women with screen-detected breast carcinoma, a delay to diagnosis greater than six months is associated with an increased risk of larger tumours and lymph node metastases compared with cases diagnosed less than one month after an abnormal screen. The tendency for physicians to more promptly refer women with highsuspicion screens is an important factor to be taken into account in the analysis of the effect of diagnostic delays on prognostic indicators of breast carcinoma.
